Clinical Trials
533
Active:30
Completed:62
Trial Phases
6 Phases
Early Phase 1:12
Phase 1:41
Phase 2:102
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (374 trials with phase data)• Click on a phase to view related trials
Not Applicable
165 (44.1%)Phase 2
102 (27.3%)Phase 1
41 (11.0%)Phase 4
34 (9.1%)Phase 3
20 (5.3%)Early Phase 1
12 (3.2%)Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Not Applicable
Not yet recruiting
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT07209163
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Not Applicable
Recruiting
- Conditions
- Rectal CancerTargeted TherapyRectal AdenocarcinomaImmunotherapyRectal Cancer, RadiotherapyRectal Cancer PatientsTotal Neoadjuvant TherapyTotal Neoadjuvant TreatmentChemoradiotherapy
- Interventions
- Drug: PD-1 inhibitor based immunotherapy
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT07198165
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Dietary Restriction Efficiency Assessment of Different Hypoallergenic Formulas in Patients With Suspected Cow's Milk Protein Allergy
Not Applicable
Not yet recruiting
- Conditions
- Cow's Milk Protein Allergy
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT07199023
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Not Applicable
Recruiting
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- Drug: orelabrutinib maintenance
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT07199296
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
Not Applicable
Not yet recruiting
- Conditions
- Acute Graft Versus Host Disease Grade II-IVAcute Graft vs Host Disease
- Interventions
- Drug: Gecacitinib
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT07197112
- Prev
- 1
- 2
- 3
- 4
- 5
- 107
- Next
News
Zambon Secures Chinese Approval for Intravenous Fluimucil Following Successful Phase 3 Trial
Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion.
CirCode Biomed's HM2002 Becomes World's First Circular RNA Drug to Receive FDA IND Clearance for Ischemic Heart Disease
CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment.